FDA Submission Update for MEZOFY (Aripiprazole) by CMG PHARM CO LTD
CMG PHARM CO LTD has submitted a supplemental application for MEZOFY (Aripiprazole) under NDA211448.
Asset / Drug
Drug and asset intelligence for MEZOFY with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.